<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04672824</url>
  </required_header>
  <id_info>
    <org_study_id>RVF002</org_study_id>
    <nct_id>NCT04672824</nct_id>
  </id_info>
  <brief_title>A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy Adults</brief_title>
  <official_title>A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Rift Valley Fever Virus (RVFV) Vaccine ChAdOx1 RVF Among Healthy Adult Volunteers in Uganda</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MRC/UVRI and LSHTM Uganda Research Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomised, single blind, placebo - controlled, dose-escalation, phase I clinical trial&#xD;
      recruiting healthy adults aged 18-50 years&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the safety profile of the candidate vaccine ChAdOx1 RVF in healthy adult volunteers in Uganda: AE</measure>
    <time_frame>The study duration: 3 months from vaccination</time_frame>
    <description>Occurrence of solicited local reactogenicity signs and symptoms for 7 days following the vaccination, occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following the vaccination, occurrence of unsolicited adverse events for 28 days following the vaccination, and occurrence of serious adverse events during the whole study duration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the safety profile of the candidate vaccine ChAdOx1 RVF in healthy adult volunteers in Uganda: change in baseline: AE</measure>
    <time_frame>The study duration: 3 months from vaccination</time_frame>
    <description>Change from baseline for safety laboratory measures: clinical blood test adverse events (full blood count, liver function tests and renal function) graded on a scaled adapted from the FDA healthy volunteer vaccine scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the immunogenicity of the candidate vaccine ChAdOx1 RVF in healthy adult volunteers in Uganda: GnGc protein antibodies</measure>
    <time_frame>The study duration: 3 months from vaccination</time_frame>
    <description>Measures of immunogenicity to the ChAdOx1 RVF vaccine:&#xD;
* ELISA to quantify antibodies to GnGc proteins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the immunogenicity of the candidate vaccine ChAdOx1 RVF in healthy adult volunteers in Uganda: RVFV neutralising antibodies</measure>
    <time_frame>The study duration: 3 months from vaccination</time_frame>
    <description>Measures of immunogenicity to the ChAdOx1 RVF vaccine:&#xD;
* RVFV neutralising antibody titres</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the immunogenicity of the candidate vaccine ChAdOx1 RVF in healthy adult volunteers in Uganda: ELISpot &amp; flow cytometry</measure>
    <time_frame>The study duration: 3 months from vaccination</time_frame>
    <description>Measures of immunogenicity to the ChAdOx1 RVF vaccine:&#xD;
* Ex vivo ELISpot and flow cytometry responses to GnGc</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>RVF</condition>
  <condition>Rift Valley Fever</condition>
  <arm_group>
    <arm_group_label>ChAdOx1 RVF group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ChAdOx1 RVF 5 x 10^9 vp, delivered intramuscularly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo (Normal Saline), 0.5ml delivered intramuscularly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ChAdOx1 RVF group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ChAdOx1 RVF 2.5 x 10^10 vp, delivered intramuscularly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ChAdOx1 RVF group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ChAdOx1 RVF 5 x 10^10 vp, delivered intramuscularly</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ChAdOx1 RVF</intervention_name>
    <description>Single dose ChAdOx1 vectored vaccine</description>
    <arm_group_label>ChAdOx1 RVF group 1</arm_group_label>
    <arm_group_label>ChAdOx1 RVF group 2</arm_group_label>
    <arm_group_label>ChAdOx1 RVF group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>0.5ml saline placebo</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The volunteer must satisfy all the following criteria to be eligible for the study:&#xD;
&#xD;
          1. Male and female healthy adults aged 18 to 50 years&#xD;
&#xD;
          2. Able and willing to provide written informed consent&#xD;
&#xD;
          3. Able and willing (in the Investigator's opinion) to comply with all study requirements&#xD;
&#xD;
          4. For females only, willingness to practice continuous effective contraception (see&#xD;
             section 4.5.3 below) during the study.&#xD;
&#xD;
          5. Females of childbearing potential must have a negative urine β-human chorionic&#xD;
             gonadotropin (β-hCG) pregnancy test at screening and a negative urine β-hCG pregnancy&#xD;
             test immediately prior to study vaccine administration&#xD;
&#xD;
          6. Agreement to refrain from blood donation during the course of the study&#xD;
&#xD;
          7. Healthy in the investigator's clinical judgement basing on the medical history and&#xD;
             physical examination perfomed at screening&#xD;
&#xD;
          8. Healthy on the basis of clinical laboratory tests (within the institutional normal&#xD;
             laboratory reference ranges) perfomed at screening.&#xD;
&#xD;
          9. Willing to provide verifiable identification to the study team&#xD;
&#xD;
         10. Volunteer must have a means to be contacted or be willing to provide locator&#xD;
             information to the study team&#xD;
&#xD;
         11. Volunteer must pass the Test of Understanding (TOU)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The volunteer may not enter the study if any of the following apply:&#xD;
&#xD;
          1. Participation in another research study involving receipt of an investigational&#xD;
             product in the 30 days preceding enrolment, or planned use during the study period&#xD;
&#xD;
          2. Prior receipt of an investigational vaccine as it may impact on interpretation of the&#xD;
             trial data.&#xD;
&#xD;
          3. Administration of immunoglobulins and/or any blood products within the three months&#xD;
             preceding the planned administration of the vaccine candidate&#xD;
&#xD;
          4. Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV&#xD;
             infection; asplenia; recurrent, severe infections and chronic (more than 14 days)&#xD;
             immunosuppressant medication within the past 6 months (inhaled and topical steroids&#xD;
             are allowed)&#xD;
&#xD;
          5. History of allergic disease or reactions likely to be exacerbated by any component of&#xD;
             the vaccine&#xD;
&#xD;
          6. Any history of hereditary angioedema, acquired angioedema, or idiopathic angioedema.&#xD;
&#xD;
          7. Any history of anaphylaxis in relation to vaccination&#xD;
&#xD;
          8. Pregnancy, lactation or willingness/intention to become pregnant during the study&#xD;
&#xD;
          9. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in&#xD;
             situ)&#xD;
&#xD;
         10. History of serious psychiatric condition likely to affect participation in the study&#xD;
&#xD;
         11. Bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or&#xD;
             prior history of significant bleeding or bruising following IM injections or&#xD;
             venepuncture&#xD;
&#xD;
         12. Acute illness or temperature ≥37.5°C/99.5°F on the day of vaccination. Volunteer may&#xD;
             be rescheduled for enrolment at a later date.&#xD;
&#xD;
         13. Major surgery (per the investigator's judgement) within 4 weeks prior to screening or&#xD;
             planned major surgery through the course of the study&#xD;
&#xD;
         14. Any other serious chronic illness requiring hospital specialist supervision&#xD;
&#xD;
         15. Suspected or known current alcohol abuse as defined by an alcohol intake of greater&#xD;
             than 14 units every week&#xD;
&#xD;
         16. Suspected or known injecting drug abuse in the 5 years preceding enrolment&#xD;
&#xD;
         17. Seropositive for hepatitis B surface antigen (HBsAg)&#xD;
&#xD;
         18. Seropositive for hepatitis C virus (antibodies to HCV)&#xD;
&#xD;
         19. Any clinically significant abnormal finding on screening biochemistry, haematology and&#xD;
             coagulation blood tests or urinalysis&#xD;
&#xD;
         20. Any other significant disease, disorder or finding which may significantly increase&#xD;
             the risk to the volunteer because of participation in the study, affect the ability of&#xD;
             the volunteer to participate in the study or impair interpretation of the study data&#xD;
&#xD;
         21. Prior natural exposure to RVFV as determined by seropositivity for RVFV antigens by&#xD;
             ELISA.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pontiano Kaleebu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MRC/UVRI and LSHTM Uganda Research Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>George Warimwe, DPhil</last_name>
    <phone>01865 611424</phone>
    <email>vaccinetrials@ndm.ox.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>MRC/UVRI and LSHTM Uganda Research Unit</name>
      <address>
        <city>Entebbe</city>
        <country>Uganda</country>
      </address>
    </facility>
    <contact>
      <last_name>George Warimwe</last_name>
      <phone>+256 (0) 485 660 490</phone>
    </contact>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rift Valley Fever</keyword>
  <keyword>Vaccine</keyword>
  <keyword>ChAdOx1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coccidioidomycosis</mesh_term>
    <mesh_term>Coccidiosis</mesh_term>
    <mesh_term>Rift Valley Fever</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

